James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Cypress Semiconductor Corporation (CY), Eagle Pharmaceuticals Inc (EGRX) and Energy Transfer Equity LP (ETE) Are 3 of Today’s Worst Stocks

Cypress Semiconductor (CY), Eagle Pharmaceuticals (EGRX) and Energy Transfer Equity (ETE) were left out of Monday's mostly market-wide rally.

WMT Stock: Wal-Mart Stores, Inc. Is Making All the Right Choices in China

Walmart (WMT) continues to evolve, with the latest growing pains stemming from the decision to cut e-commerce bait in China.

Apple Inc.’s Second-Largest Market Fights Back, Bans iPhone 6 (AAPL)

Apple (AAPL) stock is under pressure again on Friday following news that Beijing has found another way to make life difficult in China.

JNJ Stock: Johnson & Johnson Can’t Walk the Long-Term Walk

Johnson & Johnson (JNJ) has been one of 2016' most rewarding stocks, but what if there's no room for an encore?

Why American Airlines Group Inc (AAL), BioMarin Pharmaceutical Inc. (BMRN) and Cavium Inc (CAVM) Are 3 of Today’s Worst Stocks

Too bad for owners of American Airlines (AAL), BioMarin Pharmaceutical (BMRN) and Cavium (CAVM) the market doesn't do do-overs.